Those who follow my work closely know that I have a pretty solid track record with my investment calls. But every so often, I, like anybody else, can make a mistake. Admitting to shortcomings is one of the most important things that Crude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential. Subscribers get to use a 50+ stock model account, in-depth cash ...

Core Insights - Agilon Health (AGL) reported $1.45 billion in revenue for Q3 2024, a year-over-year increase of 19.4% [1] - The EPS for the same period was -$0.29, compared to -$0.06 a year ago, indicating a significant decline [1] - Revenue fell short of the Zacks Consensus Estimate of $1.47 billion by 1.29%, while the EPS surprise was -190.00% against the consensus estimate of -$0.10 [1] Financial Metrics - Average Medicare Advantage membership reached 535,000, exceeding the average estimate of 514,093 based on two analysts [3] - Revenue from medical services was $1.45 billion, compared to the estimated $1.47 billion by six analysts, reflecting a 19.4% increase year-over-year [3] - Revenue from other operating activities was $3.24 million, slightly below the estimated $3.27 million, showing an 8.3% decline compared to the previous year [3] Stock Performance - Agilon's shares have returned -7.7% over the past month, contrasting with the Zacks S&P 500 composite's +3.2% change [4] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [4]

Financial Performance - Agilon Health reported a quarterly loss of $0.29 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, and compared to a loss of $0.06 per share a year ago, indicating a significant earnings surprise of -190% [1] - The company posted revenues of $1.45 billion for the quarter ended September 2024, missing the Zacks Consensus Estimate by 1.29%, and this represents an increase from year-ago revenues of $1.22 billion [2] - Over the last four quarters, Agilon has surpassed consensus EPS estimates only once, and it has topped consensus revenue estimates just once as well [2] Stock Performance - Agilon shares have declined approximately 77.1% since the beginning of the year, contrasting sharply with the S&P 500's gain of 24.3% [3] - The current Zacks Rank for Agilon is 4 (Sell), indicating expectations for the stock to underperform the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.15 on revenues of $1.47 billion, and for the current fiscal year, it is -$0.39 on revenues of $6.02 billion [7] - The estimate revisions trend for Agilon is currently unfavorable, which could change following the recent earnings report [6] Industry Context - The Medical Services industry, to which Agilon belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, suggesting that the outlook for the industry can significantly impact stock performance [8] - Another company in the same industry, Aclarion, Inc. (ACON), is expected to report a quarterly loss of $0.18 per share, reflecting a year-over-year change of +90.6% [9]

Table of Contents Emerging Growth Company o UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fr ...

Exhibit 99.1 agilon health Reports Third Quarter 2024 Results Revenue increased 28% to $1.45 billion, Medicare Advantage membership increased 37% to 525,000, and total members on the agilon platform grew 39% to 657,000 Third quarter results were affected by lower-than-expected 2024 risk adjustment, negative prior year development mainly from risk adjustment and Part D, and higher current year medical expenses Adjusted full year guidance reflects Q3 results and updated Q4 cost trends AUSTIN, T.X., November 7 ...

Core Viewpoint - Agilon Health has experienced significant stock price declines following disappointing financial results, despite showing strong revenue growth and an interesting business model in the healthcare sector [2][3][16]. Financial Performance - In Q2 2024, Agilon Health generated revenue of $1.48 billion, a 38.7% increase from $1.07 billion in the same quarter last year, although it fell short of analysts' expectations by $60 million [4][5]. - The company reported a net loss of $30.7 million, nearly doubling from $16.7 million a year earlier, with a loss per share of $0.07, which was slightly better than analysts' expectations [5][6]. - Operating cash flow improved from negative $21.2 million to negative $18.7 million, and adjusted operating cash flow turned positive at $14.8 million [5][6]. Membership Growth - The number of Medicare Advantage members increased to 512,800 from 372,800 a year ago, but declined from 522,800 in Q1 2024, leading to market disappointment [5][8]. - ACO Model members rose significantly to 131,700 from 87,000 year-over-year, exceeding management's forecast [5][8]. Guidance and Outlook - For FY 2024, management updated guidance for Medicare Advantage members to between 518,000 and 520,000, while revenue expectations were lowered to between $6.01 billion and $6.04 billion [7][8]. - The forecast for adjusted EBITDA remains negative, projected between $15 million and $60 million [8]. Cost Management - Medical margin, defined as medical services revenue after expenses, is expected to improve to $400 million from $298.7 million in 2023, indicating a slight increase in margin percentage [11]. - Platform support costs decreased from $42 million to a lower percentage of sales, indicating better control over operating expenses [13]. Cash Position - The company's net cash position decreased to $371.8 million from $388.6 million in Q1 2024, raising concerns about potential future dilution if cash reserves continue to decline [14][15]. Valuation Considerations - The analysis suggests that while the company shows potential for growth, the current share price may not reflect an attractive investment opportunity given the volatility and uncertainty in its financial performance [16].

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agilon Health, Inc. (NYSE: AGL) on behalf of long-term stockholders following a class action complaint that was filed against Agilon on March 19, 2024 with Class Period (1) Agilon common stock purchases traceable to the April 2021 initial public offering of Agilon stock; (2) pursuant, or traceable, or both, to materials issued in connection w ...

Magilon health, inc. (NYSE:AGL) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Leland Thomas - VP, IR Steven Sell - CEO Jeffrey Schwaneke - CFO Conference Call Participants Lisa Gill - JPMorgan Justin Lake - Wolfe Research Stephen Baxter - Wells Fargo Ryan Daniels - William Blair Elizabeth Anderson - Evercore ISI Adam Ron - Bank of America. Eduardo Ron - Truist George Hill - Deutsche Bank Michael Ha - Baird Jack Slevin - Jefferies Whit Mayo - Leerink Partners Jenny Shen - BT ...

Agilon Health (AGL) reported $1.48 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 29%. EPS of -$0.07 for the same period compares to -$0.04 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.56 billion, representing a surprise of -4.85%. The company has not delivered EPS surprise, with the consensus EPS estimate being -$0.07.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how th ...

Agilon Health (AGL) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this senior-focused health care company would post a loss of $0.02 per share when it actually produced earnings of $0.01, delivering a surprise of 150%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Agilon, which belo ...